The present disclosure relates to therapies for cardiac conditions. More particularly, the present disclosure relates to methods and systems for ablation of cardiac tissue for treating cardiac arrhythmias.
Aberrant conductive pathways disrupt the normal path of the heart's electrical impulses. The aberrant conductive pathways can create abnormal, irregular, and sometimes life-threatening heart rhythms called arrhythmias. Ablation is one way of treating arrhythmias and restoring normal conduction. The aberrant pathways, and/or their sources, may be located or mapped using mapping electrodes situated in a desired location. After mapping, the physician may ablate the aberrant tissue. In radio frequency (RF) ablation, RF energy may be directed from the ablation electrode through tissue to another electrode to ablate the tissue and form a lesion.
Embodiments of the present invention facilitate real-time electrogram morphology analysis. Electrodes are used to measure an electrical signal (e.g., an electrogram), which may be, for example, a unipolar signal, a bipolar signal, and/or the like. In embodiments, an “electrical signal” may be, refer to, and/or include a signal detected by a single electrode (e.g., a unipolar signal), a signal detected by two or more electrodes (e.g., a bipolar signal), a plurality of signals detected by one or more electrodes, and/or the like. One or more filters are applied to the electrical signal to generate one or more filtered signals. Features of the filtered signals are evaluated to assess a sharpness corresponding to the electrical signal. Based on the sharpness, various characteristics of a morphology of the electrogram may be evaluated over a time period.
In Example 1, a system comprises a catheter that includes a flexible catheter body having a distal portion and at least one electrode disposed on the distal portion, the at least one electrode configured to measure an electrical signal based on a cardiac activation signal. The system also includes a mapping processor configured to acquire the electrical signal from the at least one electrode, generate an electrogram based on the electrical signal, determine a sharpness associated with the electrogram, and/or determine, based on the sharpness, a characteristic of a morphology of the electrogram.
In Example 2, the system of Example 1, further comprising a display device configured to display an indication associated with at least one of the sharpness and the characteristic of the morphology of the electrogram, wherein the characteristic of the morphology of the electrogram comprises a feature related to the sharpness; and an output component configured to provide an output to the display device, wherein the output comprises the sharpness and/or the determined feature.
In Example 3, the system of any of Examples 1 and 2, wherein the catheter comprises an ablation catheter including a tissue ablation electrode configured to apply ablation energy to tissue, the system further comprising a radiofrequency (RF) generator operatively coupled to the tissue ablation electrode, wherein the RF generator is configured to generate the ablation energy and convey the generated ablation energy to the tissue ablation electrode.
In Example 4, the system of Example 3, wherein the mapping processor is configured to determine the sharpness before an ablation, during an ablation, and/or after an ablation.
In Example 5, the system of any of Examples 2-4, wherein the mapping processor comprises: a filter configured to filter the electrical signal to generate a filtered signal; and a feature detector configured to determine an amplitude of the filtered signal, wherein the determined feature comprises the determined amplitude of the filtered signal, wherein the display device is configured to indicate a relative change in the amplitude of the filtered signal during a period of time.
In Example 6, the system of Example 5, wherein the amplitude comprises at least one of an absolute amplitude, a root-mean-squared (RMS) measurement, a peak-to-peak measurement, a maximum of a peak-to-peak measurement over a window, a percentile range measurement, a beat-gated measurement, and a free-running measurement.
In Example 7, the system of any of Examples 5 and 6, wherein the filter is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.
In Example 8, the system of any of Examples 5-7, wherein the filtered signal comprises an approximate derivative of the electrical signal.
In Example 9, the system of any of Examples 5-8, wherein the filter includes a nonlinear processing element configured to attenuate one or more components of the electrical signal based on a polarity of a deflection of the electrical signal.
In Example 10, the system of Example 9, wherein the filter comprises a half-wave rectifier.
In Example 11, the system of any of Examples 2-10, the mapping processor comprising: a first filter configured to filter the electrical signal across a first time scale to generate a first filtered signal, wherein the first filter comprises a first frequency response; a second filter configured to filter the electrical signal across a second time scale to generate a second filtered signal, wherein the second filter comprises a second frequency response, wherein at least a portion of the frequency response of the second filter is lower than a corresponding portion of the frequency response of the first filter; and a feature detector configured to determine a feature corresponding to sharpness by analyzing the first and second filtered signals, wherein the display device is configured to depict a change in the determined feature over time.
In Example 12, the system of Example 11, wherein at least one of the first and second filters is configured to determine at least one of a time difference of the electrical signal, an approximate derivative of the electrical signal, a slope estimate across a time window, and a wavelet decomposition of the electrical signal.
In Example 13, the system of any of Examples 11 and 12, wherein at least one of the first and second filters is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.
In Example 14, the system of any of Examples 1-13, wherein the mapping processor is further configured to determine an overall morphology change of the electrogram based on a pre-ablation deflection template.
In Example 15, the system of Example 14, wherein the change in morphology is determined using at least one of a matched filter, a correlation, and a convolution with the pre-ablation deflection template or a signal derived therefrom.
In Example 16, the system of any of Examples 2-15, wherein the display device is configured to display a waveform.
In Example 17, the system of Example 16, the waveform representing at least one of the filtered signal, an envelope of the filtered signal, an amplitude of the filtered signal, and a power of the filtered signal.
In Example 18, the system of any of Examples 16 and 17, wherein the output component is configured to determine a combined signal comprising a combination of the filtered signal with an additional filtered signal, the waveform representing at least one of the combined signal, an envelope of the combined signal, an amplitude of the combined signal, and a power of the combined signal.
In Example 19, a method for evaluating a condition of myocardial tissue, the method comprising: positioning a catheter adjacent to myocardial tissue within a patient's body, the catheter comprising: a flexible catheter body having a distal portion; and at least one electrode disposed on the distal portion, the at least one electrode configured to measure an electrical signal based on a cardiac activation signal; receiving the electrical signal; providing an electrogram based on the electrical signal; determining at least one of a sharpness of the electrogram and a characteristic of a morphology of the electrogram, the characteristic of the morphology of the electrogram relating to the sharpness; and displaying at least one of an indication of the sharpness and an indication of the characteristic of the morphology, wherein the indication comprises at least one of a map, a light indicator, and a waveform.
In Example 20, the method of Example 19, wherein the catheter comprises an ablation catheter including a tissue ablation electrode configured to apply ablation energy to tissue, the method further comprising performing an ablation of a portion of the tissue.
In Example 21, method of Example 20, further comprising determining the characteristic of the morphology of the electrogram before an ablation, during an ablation, and/or after an ablation.
In Example 22, the method of any of Examples 19-21, further comprising filtering, using a filter, the electrical signal to generate a filtered signal.
In Example 23, the method of Example 22, wherein the electrical signal is unipolar, and wherein filtering the electrical signal comprises applying a nonlinear processing technique to the electrogram to retain only negative deflections.
In Example 24, the method of any of Examples 22 and 23, wherein filtering the electrical signal comprises approximating a derivative of the electrical signal, the method further comprising determining a relative change in an amplitude of the filtered signal during a period of time, wherein the indication of the characteristic of the morphology indicates the relative change in the amplitude of the filtered signal during the period of time.
In Example 25, the method of Example 24, wherein the amplitude comprises at least one of an absolute amplitude, a root-mean-squared (RMS) measurement, a peak-to-peak measurement, a maximum of a peak-to-peak measurement over a window, a percentile range measurement, a beat-gated measurement, and a free-running measurement.
In Example 26, the method of any of Examples 22-25, wherein the filter is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.
In Example 27, the method of any of Examples 22-26, wherein the filter includes a nonlinear processing element configured to attenuate one or more components of the electrical signal based on a polarity of a deflection of the electrical signal.
In Example 28, the method of any of Examples 22-27, wherein the filter comprises a half-wave rectifier.
In Example 29, the method of any of Examples 19-28, further comprising: filtering the electrical signal across a first time scale to generate a first filtered signal, wherein the first filter comprises a first frequency response; filtering the electrical signal across a second time scale to generate a second filtered signal, wherein the second filter comprises a second frequency response, wherein at least a portion of the frequency response of the second filter is lower than a corresponding portion of the frequency response of the first filter; determining a feature corresponding to sharpness by analyzing the first and second filtered signals; and providing an output to a display device, wherein the output comprises the determined feature, wherein the display device is configured to depict a change in the determined feature over time.
In Example 30, the method of Example 29, wherein at least one of the first and second filters is configured to determine at least one of a time difference of the electrical signal, a derivative of the electrical signal, a slope estimate across a time window, and a wavelet decomposition of the electrical signal.
In Example 31, the method of any of Examples 29 and 30, wherein at least one of the first and second filters is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.
In Example 32, the method of any of Examples 19-31, further comprising determining an overall morphology change of the electrogram based on a pre-ablation deflection template.
In Example 33, the method of Example 32, wherein the change in morphology is determined using at least one of a matched filter, a correlation, and a convolution with the pre-ablation deflection template or a signal derived therefrom.
In Example 34, the method of any of Examples 19-33, the waveform representing at least one of the filtered signal, an envelope of the filtered signal, an amplitude of the filtered signal, and a power of the filtered signal.
In Example 35, the method of any of Examples 19-34, further comprising determining a combined signal comprising a combination of the filtered signal with an additional filtered signal, the waveform representing at least one of the combined signal, an envelope of the combined signal, an amplitude of the combined signal, and a power of the combined signal.
In Example 36, a system includes a catheter including a flexible catheter body having a distal portion; and at least one electrode disposed on the distal portion, the at least one electrode configured to measure an electrical signal based on a cardiac activation signal. The system also includes a mapping processor configured to acquire the electrical signal from the at least one electrode, provide an electrogram based on the electrical signal, determine at least one of a sharpness associated with the electrogram and a characteristic of a morphology of the electrogram, wherein the characteristic of the morphology of the electrogram is related to the sharpness.
In Example 37, the system of Example 36, wherein the catheter comprises an ablation catheter including a tissue ablation electrode configured to apply ablation energy to tissue, the system further comprising a radiofrequency (RF) generator operatively coupled to the tissue ablation electrode, wherein the RF generator is configured to generate the ablation energy and convey the generated ablation energy to the tissue ablation electrode.
In Example 38, the system of Example 37, wherein the mapping processor is configured to determine the sharpness before an ablation, during an ablation, and/or after an ablation.
In Example 39, the system of Example 36, further comprising a display device, wherein the mapping processor comprises: a filter configured to filter the electrical signal to generate a filtered signal; a feature detector configured to determine an amplitude of the filtered signal; and an output component configured to provide an output to the display device, wherein the output comprises the determined amplitude of the filtered signal.
In Example 40, the system of Example 39, wherein the amplitude comprises at least one of an absolute amplitude, a root-mean-squared (RMS) measurement, a peak-to-peak measurement, a maximum of a peak-to-peak measurement over a window, a percentile range measurement, a beat-gated measurement, and a free-running measurement.
In Example 41, the system of Example 39, wherein the filter is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.
In Example 42, the system of Example 39, wherein the filtered signal comprises an approximate derivative of the electrical signal.
In Example 43, the system of Example 39, wherein the filter includes a nonlinear processing element configured to attenuate one or more components of the electrical signal based on a polarity of a deflection of the electrical signal.
In Example 44, the system of Example 43, wherein the filter comprises a half-wave rectifier.
In Example 45, the system of Example 39, wherein the display device is configured to indicate a relative change in the amplitude of the filtered signal during a period of time.
In Example 46, the system of Example 39, wherein the display device is configured to display a waveform.
In Example 47, the system of Example 46, the waveform representing at least one of the filtered signal, an envelope of the filtered signal, an amplitude of the filtered signal, and a power of the filtered signal.
In Example 48, the system of Example 46, wherein the output component is configured to determine a combined signal comprising a combination of the filtered signal with an additional filtered signal, the waveform representing at least one of the combined signal, an envelope of the combined signal, an amplitude of the combined signal, and a power of the combined signal.
In Example 49, the system of Example 36, further comprising a display device, the mapping processor comprising: a first filter configured to filter the electrical signal across a first time scale to generate a first filtered signal, wherein the first filter comprises a first frequency response; a second filter configured to filter the electrical signal across a second time scale to generate a second filtered signal, wherein the second filter comprises a second frequency response, wherein at least a portion of the frequency response of the second filter is lower than a corresponding portion of the frequency response of the first filter; a feature detector configured to determine a feature corresponding to sharpness by analyzing the first and second filtered signals; and an output component configured to provide an output to the display device, wherein the output comprises the determined feature, wherein the display device is configured to depict a change in the determined feature over time.
In Example 50, the system of Example 49, wherein at least one of the first and second filters is configured to determine at least one of a time difference of the electrical signal, an approximate derivative of the electrical signal, a slope estimate across a time window, and a wavelet decomposition of the electrical signal.
In Example 51, the system of Example 49, wherein at least one of the first and second filters is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.
In Example 52, the system of Example 49, wherein the feature detector is configured to assess the sharpness of the electrical signal by comparing one or more levels of the first filtered signal with one or more levels of the second filtered signal to determine an amplitude-invariant measure of sharpness.
In Example 53, the system of Example 36, wherein the mapping processor is further configured to determine an overall morphology change of the electrogram based on a pre-ablation deflection template.
In Example 54, the system of Example 53, wherein the change in morphology is determined using at least one of a matched filter, a correlation, and a convolution with the pre-ablation deflection template or a signal derived therefrom.
In Example 55, a method for evaluating a condition of myocardial tissue includes positioning a catheter adjacent to myocardial tissue within a patient's body, the catheter including a flexible catheter body having a distal portion, at least one electrode disposed on the distal portion, wherein the at least one electrode is configured to measure an electrical signal based on a cardiac activation signal; receiving the electrical signal; providing an electrogram based on the electrical signal; determining at least one of a sharpness of the electrogram and a characteristic of a morphology of the electrogram, the characteristic of the morphology of the electrogram relating to the sharpness of the electrogram; and displaying an indication of at least one of the sharpness and the characteristic of the morphology, wherein the indication comprises at least one of a map, a light indicator, and a waveform.
In Example 56, the method of Example 55, wherein the catheter comprises an ablation catheter including a tissue ablation electrode configured to apply ablation energy to tissue, the method further comprising performing an ablation of a portion of the tissue.
In Example 57, the method of Example 56, further comprising determining the characteristic of the morphology of the electrogram before an ablation, during an ablation, and/or after an ablation.
In Example 58, the method of Example 55, further comprising filtering, using a filter, the electrical signal to generate a filtered signal.
In Example 59, the method of Example 58, wherein the electrical signal is unipolar, and wherein filtering the electrical signal comprises applying a nonlinear processing technique to the electrogram to retain only negative deflections.
In Example 60, the method of Example 59, wherein applying the nonlinear processing technique comprises applying a half-wave rectifier to the electrogram.
In Example 61, the method of Example 58, wherein filtering the electrical signal comprises approximating a derivative of the electrical signal, the method further comprising determining a relative change in an amplitude of the filtered signal during a period of time, wherein the indication of the characteristic of the morphology indicates the relative change in the amplitude of the filtered signal during the period of time.
In Example 62, the method of Example 61, wherein the amplitude comprises at least one of an absolute amplitude, a root-mean-squared (RMS) measurement, a peak-to-peak measurement, a maximum of a peak-to-peak measurement over a window, a percentile range measurement, a beat-gated measurement, and a free-running measurement.
In Example 63, the method of Example 58, wherein the filter is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.
In Example 64, the method of Example 55, further comprising: filtering the electrical signal across a first time scale, using a first filter, to generate a first filtered signal, wherein the first filter comprises a first frequency response; filtering the electrical signal across a second time scale, using a second filter, to generate a second filtered signal, wherein the second filter comprises a second frequency response, wherein at least a portion of the frequency response of the second filter is lower than a corresponding portion of the frequency response of the first filter; determining a feature corresponding to sharpness by analyzing the first and second filtered signals; and providing an output to a display device, wherein the output comprises the determined feature, wherein the display device is configured to depict a change in the determined feature over time.
In Example 65, the method of Example 64, wherein at least one of the first and second filters is configured to determine at least one of a time difference of the electrical signal, a derivative of the electrical signal, a slope estimate across a time window, and a wavelet decomposition of the electrical signal.
In Example 66, the method of Example 64, wherein at least one of the first and second filters is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.
In Example 67, the method of Example 64, further comprising determining an overall morphology change of the electrogram based on a pre-ablation deflection template.
In Example 68, the method of Example 67, wherein the change in morphology is determined using at least one of a matched filter, a correlation, and a convolution with the pre-ablation deflection template or a signal derived therefrom.
In Example 69, the method of Example 64, the waveform representing at least one of the filtered signal, an envelope of the filtered signal, an amplitude of the filtered signal, and a power of the filtered signal.
In Example 70, the method of Example 65, further comprising determining a combined signal comprising a combination of the filtered signal with an additional filtered signal, the waveform representing at least one of the combined signal, an envelope of the combined signal, an amplitude of the combined signal, and a power of the combined signal.
In Example 71, a system includes an ablation catheter including a flexible catheter body having a distal portion, a tissue ablation electrode disposed on the distal portion of the flexible catheter body, wherein the tissue ablation electrode is configured to apply ablation energy to tissue. The system also includes at least one electrode disposed on the distal portion, the at least one electrode configured to measure an electrical signal based on a cardiac activation signal; and a radiofrequency (RF) generator operatively coupled to the tissue ablation electrode and configured to generate the ablation energy to be conveyed to the tissue ablation electrode. The system further includes a mapping processor configured to: acquire the electrical signal from the at least one electrode; provide an electrogram based on the electrical signal; determine at least one of a sharpness associated with the electrogram and a characteristic of a morphology of the electrogram, the characteristic relating to the sharpness.
While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.
Electrophysiologists may utilize any number of metrics to assess the formation and transmurality of lesions. These include, for example, bipolar electrogram amplitude drop, ablation impedance drop, and pacing capture threshold. Electrogram amplitude, measured from peak to peak of a given bipolar electrogram deflection, provides a measure of myocardium viability. However, it does not quantify the morphology of the electrogram, which may contain additional information about lesion formation, especially in unhealthy tissue. In unhealthy tissue (e.g., tissue afflicted by edema, scar tissue, etc.), amplitude reduction due to damage to the local surviving tissue may be obscured by the much stronger far-field signal. However, damage to the local tissue may make some components of the electrogram change less rapidly as compared to when the local tissue was healthy. Quantifying electrogram morphology before, during, and after an ablation, by analyzing sharpness of the electrogram, may facilitate aiding electrophysiologists in evaluating the formation of lesions. Real-time morphology analysis may facilitate enabling electrophysiologists to determine a minimum amount of time required for each ablation, reducing the amount of radiofrequency (RF) energy delivered during procedures.
According to various embodiments, measuring sharpness may include assigning a time-varying value to an electrogram. For example, sharpness may be quantified using an approximate derivative calculated at various temporal scales. The values may be used, in a relative manner, throughout an ablation in order to gauge the progressive change of morphology. Embodiments of the invention may be implemented using specialty catheters or catheters already commercially available. Embodiments include a hardware/software graphical user interface (GUI) used for acquiring electrical signals, performing sharpness analyses, and displaying the results during an ablation procedure. This may be accomplished, for example, with a stand-alone system or may be incorporated into existing systems such as the Bard LabSystem Pro or the Rhythmia Mapping System, both available from Boston Scientific Corporation of Marlborough, Mass.
In some instances, the ablation system 100 may be utilized in ablation procedures on a patient and/or in ablation procedures on other objects. In various embodiments, the ablation catheter 102 may be configured to be introduced into or through the vasculature of a patient and/or into or through any other lumen or cavity. In an example, the ablation catheter 102 may be inserted through the vasculature of the patient and into one or more chambers of the patient's heart (e.g., a target area). When in the patient's vasculature or heart, the ablation catheter 102 may be used to map and/or ablate myocardial tissue using the ring electrodes 116, the electrodes 120 and/or the tissue ablation electrode 118. In embodiments, the tissue ablation electrode 118 may be configured to apply ablation energy to myocardial tissue of the heart of a patient.
The catheter 102 may be steerable to facilitate navigating the vasculature of a patient or navigating other lumens. For example, the distal portion 114 of the catheter 102 may be configured to be deflected (as indicated by the dashed outlines in
In various embodiments, the electrodes 120 are circumferentially distributed about the tissue ablation electrode 118 and electrically isolated therefrom. The electrodes 120 can be configured to operate in unipolar or bipolar sensing modes. In some embodiments, the plurality of electrodes 120 may define and/or at least partially form one or more bipolar electrode pairs, each bipolar electrode pair being configured to measure an electrical signal corresponding to a sensed electrical activity (e.g., an electrogram (EGM) reading) of the myocardial tissue proximate thereto. The measured signals from the electrodes 120 can be provided to the mapping processor 106 for processing as described herein. In embodiments, an EGM reading or signal from a bipolar electrode pair may at least partially form the basis of a contact assessment, ablation area assessment (e.g., tissue viability assessment), and/or an ablation progress assessment (e.g., a lesion formation/maturation analysis), as discussed below.
Various embodiments may include, instead of, or in addition to, an ablation catheter 102, a mapping catheter (not shown) that includes mapping electrodes such as, for example, the electrodes 120, but does not necessarily include a tissue ablation electrode 118. In embodiments, for example, a mapping catheter may be utilized for mapping while performing an ablation with a separate ablation catheter (e.g., the ablation catheter 102), or independently of performing tissue ablation. In other embodiments, more than one mapping catheter may be used to enhance the mapping data. Additionally or alternatively to the circumferentially spaced electrodes 120, the catheter 102 may include one or more forward facing electrodes (not shown). The forward facing electrodes may be generally centrally located within the tissue ablation electrode 118 and/or at an end of a tip of the catheter 102.
The tissue ablation electrode 118 may be any length and may have any number of the electrodes 120 positioned therein and spaced circumferentially and/or longitudinally about the tissue ablation electrode 118. In some instances, the tissue ablation electrode 118 may have a length of between one (1) mm and twenty (20) mm, three (3) mm and seventeen (17) mm, or six (6) mm and fourteen (14) mm. In one illustrative example, the tissue ablation electrode 118 may have an axial length of about eight (8) mm.
In some cases, the plurality of electrodes 120 may be spaced at any interval about the circumference of the tissue ablation electrode 118. In one example, the tissue ablation electrode 118 may include at least three electrodes 120 equally or otherwise spaced about the circumference of the tissue ablation electrode 118 and at the same or different longitudinal positions along the longitudinal axis of the tissue ablation electrode 118. In some illustrative instances, the tissue ablation electrode 118 may have an exterior wall that at least partially defines an open interior region (not shown). The exterior wall may include one or more openings for accommodating one or more electrodes 120. Additionally, or alternatively, the tissue ablation electrode 118 may include one or more irrigation ports (not shown). Illustratively, the irrigation ports, when present, may be in fluid communication with an external irrigation fluid reservoir and pump (not shown) which may be used to supply fluid (e.g., irrigation fluid) to myocardial tissue to be or being mapped and/or ablated.
The RF generator 104 may be configured to deliver ablation energy to the ablation catheter 102 in a controlled manner in order to ablate the target tissue sites identified by the mapping processor 106. Ablation of tissue within the heart is well known in the art, and thus for purposes of brevity, the RF generator 104 will not be described in further detail. Further details regarding RF generators are provided in U.S. Pat. No. 5,383,874, which is expressly incorporated herein by reference in its entirety for all purposes. Although the mapping processor 106 and RF generator 104 are shown as discrete components, they can alternatively be incorporated into a single integrated device.
The RF ablation catheter 102 as described may be used to perform various diagnostic functions to assist the physician in an ablation treatment. For example, in some embodiments, the catheter 102 may be used to ablate cardiac arrhythmias, and at the same time provide real-time assessment of a lesion formed during RF ablation. Real-time assessment of the lesion may involve any of monitoring surface and/or tissue temperature at or around the lesion, reduction in the electrocardiogram signal, a drop in impedance, direct and/or surface visualization of the lesion site, and imaging of the tissue site (e.g., using computed tomography, magnetic resonance imaging, ultrasound, etc.). In addition, the presence of the electrodes within the RF tip electrode can operate to assist the physician in locating and positioning the tip electrode at the desired treatment site, and to determine the position and orientation of the tip electrode relative to the tissue to be ablated.
Illustrative catheters that may be used as the catheter 102 may include, among other ablation and/or mapping catheters, those described in U.S. patent application Ser. No. 12/056,210 filed on Mar. 26, 2008, and entitled HIGH RESOLUTION ELECTROPHYSIOLOGY CATHETER, and U.S. Pat. No. 8,414,579 filed on Jun. 23, 2010, entitled MAP AND ABLATE OPEN IRRIGATED HYBRID CATHETER, which are both hereby incorporated herein by reference in their entireties for all purposes. Alternatively, or in addition, catheters that may be used as the catheter 102 may include, among other ablation and/or mapping catheters, those described in U.S. Pat. No. 5,647,870 filed on Jan. 16, 1996, as a continuation of U.S. Ser. No. 206,414, filed Mar. 4, 1994 as a continuation-in-part of U.S. Ser. No. 33,640, filed Mar. 16, 1993, entitled MULTIPLE ELECTRODE SUPPORT STRUCTURES, U.S. Pat. No. 6,647,281 filed on Apr. 6, 2001, entitled EXPANDABLE DIAGNOSTIC OR THERAPEUTIC APPARATUS AND SYSTEM FOR INTRODUCING THE SAME INTO THE BODY, and U.S. Pat. No. 8,128,617 filed on May 27, 2008, entitled ELECTRICAL MAPPING AND CRYO ABLATING WITH A BALLOON CATHETER, which are all hereby incorporated herein by reference in their entireties for all purposes.
In operation and when the catheter 102 is within a patient and/or adjacent a target area, the catheter 102 may sense electrical signals (e.g., EGM signals) from the patient or target area and relay those electrical signals to a physician (e.g., through the display of the RF ablation system 100). Electrophysiologists and/or others may utilize an EGM amplitude and/or EGM morphology to verify a location of the ablation catheter in a patient's anatomy, to verify viability of tissue adjacent the ablation catheter, to verify lesion formation in tissue adjacent the ablation catheter, and/or to verify or identify other characteristics related to the catheter 102 and/or adjacent target tissue or areas.
Based, at least in part, on its sensing capabilities, the catheter 102 may be utilized to perform various diagnostic functions to assist the physician in ablation and/or mapping procedures, as referred to above and discussed further below. In one example, the catheter 102 may be used to ablate cardiac arrhythmias, and at the same time provide real-time positioning information, real-time tissue viability information, and real-time assessment of a lesion formed during ablation (e.g., during RF ablation). Real-time assessment of the lesion may involve monitoring surfaces and/or tissue temperature at or around the lesion, reduction in the electrogram signal amplitude and/or spectrum, a change in impedance (e.g., an increase or decrease), direct and/or surface visualization of the lesion site, and/or imaging of a tissue site (e.g., using computed tomography, magnetic resonance imaging, ultrasound, etc.). “Real-time”, as used herein and understood in the art, means during an action or process. For example, where one is monitoring frequency spectra in real time during an ablation at a target area, the frequency spectra are being monitored during the process of ablating at a target area (e.g., between applications of ablation energy). Additionally, or alternatively, the presence of electrodes 120 at or about the tissue ablation electrode 118 and/or within the tip (e.g., at the distal tip) of the catheter 102 may facilitate allowing a physician to locate and/or position the tissue ablation electrode 118 at a desired treatment site, to determine the position and/or orientation of the tissue ablation electrode relative to the tissue that is to be ablated or relative to any other feature.
In instances where an output is generated to a display device 206 and/or other instances, the mapping processor 202 may be operatively coupled to or otherwise in communication with the display device 206. In embodiments, the display device 206 may include various static and/or dynamic information related to the use of an RF ablation system (e.g., the RF ablation system 100 depicted in
In embodiments, the display device 206 may be an indicator. The indicator may be capable of providing an indication related to a feature of the output signals received from one or more of the electrodes 204. For example, an indication to the clinician about a characteristic of the catheter and/or the myocardial tissue interacted with and/or being mapped may be provided on the display device 206. In some cases, the indicator may provide a visual and/or audible indication to provide information concerning the characteristic of the catheter and/or the myocardial tissue interacted with and/or being mapped. In embodiments, the visual indication may take one or more forms. In some instances, a visual color or light indication on a display 206 may be separate from or included on an imaged catheter on the display 206 if there is an imaged catheter. Such a color or light indicator may include a progression of lights or colors that may be associated with various levels of a characteristic proportional to the amplitude and/or spectrum of an EGM. Alternatively, or in addition, an indicator indicating a level of a characteristic proportional to an amplitude and/or spectrum of an EGM may be provided in any other manner on a display and/or with any audible or other sensory indication, as desired.
In some cases, a visual indication may be an indication on a display device 206 (e.g., a computer monitor, touchscreen device, and/or the like) with one or more lights or other visual indicators. In one example of an indicator, a color of at least a portion of an electrode of a catheter imaged on a screen of the display 206 may change from a first color (e.g., red or any other color) when there is poor contact between the catheter and tissue to a second color (e.g., green or any other color different than the first color) when there is good contact between the catheter and the tissue and/or when ablation may be initiated after establishing good contact. Additionally or alternatively in another example of an indicator, when the amplitude and/or frequency spectrum of the EGM stops changing and/or reaches a lesion maturation amplitude or frequency spectrum threshold, a depicted color of an electrode on the imaged catheter may change colors to indicate a level of lesion maturation. In a similar manner, an indicator may be utilized to indicate a viability of tissue to be ablated. In the examples above, the changing color/light or changing other indicator (e.g., a number, an image, a design, etc.) may be located at a position on the display other than on the imaged catheter, as desired. According to embodiments, indicators may provide any type of information to a user. For example, the indicators discussed herein may be pass or fail type indicators showing when a condition is present or is not present and/or may be progressive indicators showing the progression from a first level to a next level of a characteristic.
According to embodiments, various components (e.g., the mapping processor 202) of the operating environment 200, illustrated in
In embodiments, a computing device includes a bus that, directly and/or indirectly, couples the following devices: a processing unit (e.g., the processing unit 208 depicted in
In embodiments, the memory 210 includes computer-readable media in the form of volatile and/or nonvolatile memory and may be removable, nonremovable, or a combination thereof. Media examples include Random Access Memory (RAM); Read Only Memory (ROM); Electronically Erasable Programmable Read Only Memory (EEPROM); flash memory; optical or holographic media; magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices; data transmissions; or any other medium that can be used to store information and can be accessed by a computing device such as, for example, quantum state memory, and the like.
In embodiments, the memory 210 stores computer-executable instructions for causing the processing unit 208 to implement aspects of embodiments of system components and/or to perform aspects of embodiments of methods and procedures discussed herein. Computer-executable instructions may include, for example, computer code, machine-useable instructions, and the like such as, for example, program components capable of being executed by one or more processors associated with a computing device. Examples of such program components include a filter component 214 and a feature detector 216. Program components may be programmed using any number of different programming environments, including various languages, development kits, frameworks, and/or the like. Some or all of the functionality contemplated herein may also be implemented in hardware and/or firmware.
The illustrative operating environment 200 shown in
For example, in embodiments, EGM amplitude may be determined and/or measured in real-time by the mapping processor 202, e.g., from peak to peak of an EGM deflection or from the ST segment of the P-QRS-T curve of an EGM reading or signal in a time domain, and may quantify an intensity of an EGM signal and provide information relating to one or more target area characteristics. In embodiments, some target area characteristics include, but are not limited to, contact force between the catheter 102 and tissue, viability of tissue, and lesion maturation.
In some instances, EGM data may be further analyzed in a meaningful manner in real-time (e.g., during a typical electrophysiology procedure) by determining a sharpness feature associated with the EGM and determining, based on the sharpness feature, a characteristic of morphology of the EGM. In embodiments, determining the sharpness feature may include filtering an EGM signal with the mapping processor 202 and/or other processor and analyzing the resulting filtered signal or signals. Such an analysis of filtered signals derived from an EGM signal may enhance EGM data interpretation and may allow for real-time insights related to contact assessments, viable versus non-viable tissue, and/or lesion maturation during an ablation procedure, among other real-time insights.
Illustratively, any technique, as desired, may be utilized (e.g., by the filter component 214) to filter an EGM signal. For example, the filter component 214 may be configured to determine an approximate derivative of the EGM signal, apply frequency filters to the EGM signal across various time scales, apply a half-wave rectifier or other nonlinear processing to unipolar EGM signals, apply matched filters to the EGM signal, and/or the like. In embodiments, for example, the filter component 214 may be configured to filter the EGM to generate a filtered signal, and the feature detector 216 may be configured to determine a feature (e.g., an amplitude, an envelope, a power, etc.) of the filtered signal. The filter component 214 may, in embodiments, include any number of nonlinear processing elements configured to attenuate one or more components of a signal, e.g., based on the polarity of the deflection of the signal. For example, a matched filter may be used to quantify overall morphology of the EGM. For example, the filter component 214 may select a pre-ablation deflection template (or signal derived therefrom) and correlate it, and/or convolute it, with one or more deflections received during and/or after ablation. In this manner, for example, the feature detector 216 may be used to determine a maximum normalized correlation of the template with each subsequent deflection, which may represent, for example, an amplitude-independent change in morphology of the EGM over time.
The output component 212 may be configured to provide an output to the display device 206, where the output includes the determined feature (e.g., an amplitude computed over a window such as a window that is related to one or more beat events) of the filtered signal. For example, the display device 206 may be configured to indicate a relative change in the amplitude of the filtered signal during a period of time. According to embodiments, the amplitude may include a root-mean-squared (RMS) amplitude calculation, a power calculation, a peak-to-peak calculation, a percentile range calculation, a beat-gated amplitude, a free-running amplitude, and/or the like. In embodiments, the display device 206 may be configured to display a waveform. The waveform may, for example, represent the filtered signal, an envelope of the filtered signal, an amplitude of the filtered signal, a power of the filtered signal, a combined signal (e.g., a combination of the filtered signal with an additional filtered signal), an envelope of a combined signal, an amplitude of a combined signal, a power of a combined signal, and/or the like. A combined signal may, for example, be generated by averaging the filtered signal and an additional filtered signal, computing a root mean square (RMS) of the two signals, and/or the like.
As described above, in embodiments, a mapping processor (e.g., the mapping processor 106 depicted in
According to embodiments, the mapping processor determines a characteristic of morphology of the EGM based on a sharpness feature of the EGM. In embodiments, the mapping processor may filter the EGM (e.g., the electrical signal) to generate a filtered signal and determine a relative change in an amplitude of the filtered signal during a period of time. For example, the mapping processor may filter the EGM by determining an approximate derivative of the measured electrical signal, in which case the indication of the characteristic of the morphology may indicate the relative change in the amplitude of the filtered signal during the period of time, a representation of an envelope of the filtered signal, and/or the like. In embodiments, the mapping processor may determine an approximate first derivative of the EGM, an approximate second derivative of the EGM, and/or approximate derivatives of higher order. In embodiments, by discretely differentiating an EGM over a sliding time window, the mapping processor may emphasize high frequencies and evaluate the relative change in the amplitude of that differentiated EGM at activation times. Approximating a derivative may include applying a filter with a frequency response that increases roughly in proportion to frequency over some frequency range, e.g. a first difference or a first-order high-pass filter. Approximating a derivative may also include estimating the slope of a signal over some time scale, e.g. using a filter that outputs the slope of a linear regression over a sliding time window.
In some instances, an amplitude, relative amplitude, change in amplitude, and/or rate of change in amplitude of the measured electrical signal (e.g., the EGM), filtered signal, and/or the like, may also be identified and/or represented in an indication via a display device (e.g., the display device 206 depicted in
According to embodiments, a level of one or more characteristics may be represented and/or monitored via the determined characteristics of morphology of the EGM. The one or more characteristics may include, for example, contact force between the catheter and a target area (e.g., a target tissue or other target area), viability of a target area, ablation progress (e.g., lesion maturation or other metric of ablation progress), and conduction characteristics of a target area. In embodiments, one or more of these or other characteristics can be represented and/or monitored, as described herein, in real time, for example, while positioning the distal portion of the catheter proximate the target area, while mapping a target area or other object, while applying ablation energy to a target area, and/or while performing any other action with the catheter. The level of the one or more of the characteristics may be displayed visually on a display, may be indicated by an audible indicator, or may be indicated in any other manner. In embodiments, the indication may include a map (e.g., a voltage map, a frequency spectral map, etc.), a light indicator, a waveform, and/or the like.
For example, the EGM signals and/or filtered signals may be displayed on a display or screen for viewing and/or analysis by a user (e.g., a physician, technician, or other user) of the ablation system and/or mapping catheter. As an alternative, or in addition, to displaying the EGM signals and/or filtered signals, an indication of the orientation of the ablation catheter with respect to a target cardiac tissue may be displayed on a display with indicators thereon or thereabout indicating characteristics proportional to the EGM signals and/or filtered signals. Such an indication of the orientation of the catheter may facilitate the user of the ablation system in determining the orientation of the catheter with respect to the target cardiac tissue. A user of the ablation system may manipulate the catheter to modify a position of the catheter with respect to a target cardiac tissue or to change a force applied to the target cardiac tissue in order to obtain various EGM signal readings. Such manipulation of the catheter may facilitate determining the viability of the target/sensed cardiac tissue, as explained, for example, in U.S. Provisional Application No. 61/955,087, “ELECTROPHYSIOLOGY SYSTEM,” filed Mar. 18, 2014; and U.S. application Ser. No. 13/738,562, “ELECTROPHYSIOLOGY SYSTEM AND METHODS,” filed Jan. 10, 2013, each of which is hereby incorporated herein by reference in its entirety for all purposes.
Returning to
The illustrative process flow 400 shown in
According to embodiments, the first filter 608 may include a first filter, having a first frequency response, configured to filter the electrical signal 606 across a first time scale to generate the first filtered signal 612. The first filtered signal 612 may, for example, include a first frequency spectrum. Additionally, the second filter 610 may include a second filter, having a second frequency response, configured to filter the electrical signal 606 across a second time scale to generate a second filtered signal 614, and where the second filtered signal 614 includes a second frequency spectrum. In embodiments, at least a portion of the spectrum of the second filtered signal may be lower than a corresponding portion of the frequency spectrum of the first filtered signal. Additionally, in embodiments, the first filter and/or the second filter may be more responsive to high-frequency, and/or quickly-varying components, of the measured electrical signal than to low-frequency, and/or slowly-varying components of the measured electrical signal. High-frequency, low-frequency, quickly-varying, and slowly-varying components of the signal may be determined based on any number of different thresholds or ranges. In embodiments, the filter or filters may be configured to be more responsive to various components such that detection of characteristics of the sharpness of the measured electrical signal, as described herein, is enhanced and/or optimized.
According to various embodiments, at least one of the first and second filters 608 and 610 is configured to determine at least one of a time difference of the measured electrical signal 606, a derivative of the measured electrical signal 606, a slope estimate across a time window, and a wavelet decomposition of the measured electrical signal 606. In embodiments, the feature detector 616 may be configured to combine information corresponding to the first and second filtered signals 612 and 614 across time scales to assess sharpness. For example, the feature detector 616 may be configured to compare filtered signal levels at different scales (e.g., short-term vs. long-term slope) to determine an amplitude-invariant measure of sharpness. In embodiments, the feature detector 616 may be configured to evaluate any number of different characteristics associated with a comparison between the first and second filtered signals such as, for example, frequency or phase shifts, frequency spectrum tilt (e.g., an increase in the amount of high or low frequencies over time as amplitudes decrease), and/or the like.
The illustrative process flow 600 shown in
Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present invention. For example, while the embodiments described above refer to particular features, the scope of this invention also includes embodiments having different combinations of features, embodiments having additional features, and embodiments that do not include all of the described features. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.
For example, while bipolar signals have an advantage of reducing far-field signals, one disadvantage is that information in the polarity of deflection may be lost. In a bipolar electrogram, local tissue depolarization may appear as a positive deflection, a negative deflection, or both. In a unipolar electrogram (which can be processed to reduce far-field signals), only negative deflections are indicative of local tissue depolarization. Therefore, embodiments of the present invention, as described herein, may be configured to include a nonlinear processing step to retain only negative deflections, e.g., by a half-wave rectifier after filtering the unipolar EGM, which may result in reduced noise floor and better spatial selectivity.
This application claims priority to Provisional Application No. 62/093,771, filed Dec. 18, 2014, which is herein incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3773401 | Douklias et al. | Nov 1973 | A |
4466443 | Utsugi | Aug 1984 | A |
4602624 | Naples et al. | Jul 1986 | A |
4633882 | Matsuo et al. | Jan 1987 | A |
4732149 | Sutter | Mar 1988 | A |
4763660 | Kroll et al. | Aug 1988 | A |
4966145 | Kikumoto et al. | Oct 1990 | A |
5019076 | Yamanashi et al. | May 1991 | A |
5029588 | Yock et al. | Jul 1991 | A |
5178150 | Silverstein et al. | Jan 1993 | A |
5217460 | Knoepfler | Jun 1993 | A |
5238004 | Sahatjian et al. | Aug 1993 | A |
5240003 | Lancee et al. | Aug 1993 | A |
5254088 | Lundquist et al. | Oct 1993 | A |
5295482 | Clare et al. | Mar 1994 | A |
5318589 | Lichtman | Jun 1994 | A |
5324284 | Imran | Jun 1994 | A |
5331966 | Bennett et al. | Jul 1994 | A |
5334193 | Nardella | Aug 1994 | A |
5341807 | Nardella | Aug 1994 | A |
5377685 | Kazi et al. | Jan 1995 | A |
5383874 | Jackson et al. | Jan 1995 | A |
5385146 | Goldreyer | Jan 1995 | A |
5385148 | Lesh et al. | Jan 1995 | A |
5391199 | Ben-Haim | Feb 1995 | A |
5398683 | Edwards et al. | Mar 1995 | A |
5423811 | Imran et al. | Jun 1995 | A |
5447529 | Marchlinski et al. | Sep 1995 | A |
5462521 | Brucker et al. | Oct 1995 | A |
5482054 | Slater et al. | Jan 1996 | A |
5485849 | Panescu et al. | Jan 1996 | A |
5494042 | Panescu et al. | Feb 1996 | A |
5500012 | Brucker et al. | Mar 1996 | A |
5520683 | Subramaniam et al. | May 1996 | A |
5571088 | Lennox et al. | Nov 1996 | A |
5573535 | Viklund | Nov 1996 | A |
5575772 | Lennox | Nov 1996 | A |
5579764 | Goldreyer | Dec 1996 | A |
5582609 | Swanson et al. | Dec 1996 | A |
5647870 | Kordis et al. | Jul 1997 | A |
5718701 | Shai et al. | Feb 1998 | A |
5722402 | Swanson et al. | Mar 1998 | A |
5762067 | Dunham et al. | Jun 1998 | A |
5788636 | Curley | Aug 1998 | A |
5792064 | Panescu et al. | Aug 1998 | A |
5800482 | Pomeranz et al. | Sep 1998 | A |
5820568 | Willis | Oct 1998 | A |
5830213 | Panescu et al. | Nov 1998 | A |
5833621 | Panescu et al. | Nov 1998 | A |
5836990 | Li | Nov 1998 | A |
5868735 | Lafontaine | Feb 1999 | A |
5871483 | Jackson et al. | Feb 1999 | A |
5871526 | Gibbs et al. | Feb 1999 | A |
5876336 | Swanson et al. | Mar 1999 | A |
5885278 | Fleischman | Mar 1999 | A |
5913856 | Chia et al. | Jun 1999 | A |
5916213 | Haissaguerre et al. | Jun 1999 | A |
5957850 | Marian et al. | Sep 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6027500 | Buckles et al. | Feb 2000 | A |
6050267 | Nardella et al. | Apr 2000 | A |
6050994 | Sherman | Apr 2000 | A |
6059778 | Sherman | May 2000 | A |
6063078 | Wittkampf | May 2000 | A |
6064905 | Webster, Jr. et al. | May 2000 | A |
6068629 | Haissaguerre et al. | May 2000 | A |
6070094 | Swanson et al. | May 2000 | A |
6083170 | Ben-Haim | Jul 2000 | A |
6083222 | Klein et al. | Jul 2000 | A |
6099524 | Lipson et al. | Aug 2000 | A |
6101409 | Swanson et al. | Aug 2000 | A |
6116027 | Smith et al. | Sep 2000 | A |
6120476 | Fung et al. | Sep 2000 | A |
6165123 | Thompson | Dec 2000 | A |
6171305 | Sherman | Jan 2001 | B1 |
6200314 | Sherman | Mar 2001 | B1 |
6206831 | Suorsa et al. | Mar 2001 | B1 |
6210337 | Dunham et al. | Apr 2001 | B1 |
6216027 | Willis et al. | Apr 2001 | B1 |
6224557 | Ziel et al. | May 2001 | B1 |
6233491 | Kordis et al. | May 2001 | B1 |
6241754 | Swanson et al. | Jun 2001 | B1 |
6270493 | Lalonde et al. | Aug 2001 | B1 |
6290697 | Tu et al. | Sep 2001 | B1 |
6352534 | Paddock et al. | Mar 2002 | B1 |
6395325 | Hedge et al. | May 2002 | B1 |
6400981 | Govari | Jun 2002 | B1 |
6423002 | Hossack | Jul 2002 | B1 |
6475213 | Whayne et al. | Nov 2002 | B1 |
6488678 | Sherman | Dec 2002 | B2 |
6491710 | Satake | Dec 2002 | B2 |
6508767 | Burns et al. | Jan 2003 | B2 |
6508769 | Bonnefous | Jan 2003 | B2 |
6508803 | Horikawa et al. | Jan 2003 | B1 |
6516667 | Broad et al. | Feb 2003 | B1 |
6517533 | Swaminathan | Feb 2003 | B1 |
6517534 | McGovern et al. | Feb 2003 | B1 |
6537271 | Murray et al. | Mar 2003 | B1 |
6544175 | Newman | Apr 2003 | B1 |
6546270 | Goldin et al. | Apr 2003 | B1 |
6547788 | Maguire et al. | Apr 2003 | B1 |
6569160 | Goldin et al. | May 2003 | B1 |
6572547 | Miller et al. | Jun 2003 | B2 |
6575966 | Lane et al. | Jun 2003 | B2 |
6575969 | Rittman et al. | Jun 2003 | B1 |
6579278 | Bencini | Jun 2003 | B1 |
6582372 | Poland | Jun 2003 | B2 |
6584345 | Govari | Jun 2003 | B2 |
6589182 | Loftman et al. | Jul 2003 | B1 |
6592525 | Miller et al. | Jul 2003 | B2 |
6602242 | Fung et al. | Aug 2003 | B1 |
6620103 | Bruce et al. | Sep 2003 | B1 |
6632179 | Wilson et al. | Oct 2003 | B2 |
6638222 | Chandrasekaran et al. | Oct 2003 | B2 |
6640120 | Swanson et al. | Oct 2003 | B1 |
6647281 | Morency | Nov 2003 | B2 |
6656174 | Hegde et al. | Dec 2003 | B1 |
6658279 | Swanson et al. | Dec 2003 | B2 |
6663573 | Goldin | Dec 2003 | B2 |
6666862 | Jain et al. | Dec 2003 | B2 |
6676606 | Simpson et al. | Jan 2004 | B2 |
6692441 | Poland et al. | Feb 2004 | B1 |
6705992 | Gatzke | Mar 2004 | B2 |
6709396 | Flesch et al. | Mar 2004 | B2 |
6711429 | Gilboa et al. | Mar 2004 | B1 |
6719756 | Muntermann | Apr 2004 | B1 |
6735465 | Panescu | May 2004 | B2 |
6736814 | Manna et al. | May 2004 | B2 |
6743174 | Ng et al. | Jun 2004 | B2 |
6773402 | Govari et al. | Aug 2004 | B2 |
6776758 | Peszynski et al. | Aug 2004 | B2 |
6796979 | Lentz | Sep 2004 | B2 |
6796980 | Hall | Sep 2004 | B2 |
6804545 | Fuimaono et al. | Oct 2004 | B2 |
6811550 | Holland et al. | Nov 2004 | B2 |
6824517 | Salgo et al. | Nov 2004 | B2 |
6837884 | Woloszko | Jan 2005 | B2 |
6845257 | Fuimaono et al. | Jan 2005 | B2 |
6845264 | Skladnev et al. | Jan 2005 | B1 |
6917834 | Koblish et al. | Jul 2005 | B2 |
6922579 | Taimisto et al. | Jul 2005 | B2 |
6923808 | Taimisto | Aug 2005 | B2 |
6932811 | Hooven et al. | Aug 2005 | B2 |
6945938 | Grunwald | Sep 2005 | B2 |
6950689 | Willis et al. | Sep 2005 | B1 |
6952615 | Satake | Oct 2005 | B2 |
6958040 | Oliver et al. | Oct 2005 | B2 |
7001383 | Keidar | Feb 2006 | B2 |
7037264 | Poland | May 2006 | B2 |
7047068 | Haissaguerre | May 2006 | B2 |
7097643 | Cornelius et al. | Aug 2006 | B2 |
7099711 | Fuimaono et al. | Aug 2006 | B2 |
7105122 | Karason | Sep 2006 | B2 |
7112198 | Satake | Sep 2006 | B2 |
7115122 | Swanson et al. | Oct 2006 | B1 |
7123951 | Fuimaono et al. | Oct 2006 | B2 |
7131947 | Demers | Nov 2006 | B2 |
7166075 | Varghese et al. | Jan 2007 | B2 |
7181262 | Fuimaono et al. | Feb 2007 | B2 |
7220233 | Nita et al. | May 2007 | B2 |
7232433 | Schlesinger et al. | Jun 2007 | B1 |
7247155 | Hoey et al. | Jul 2007 | B2 |
7270634 | Scampini et al. | Sep 2007 | B2 |
7288088 | Swanson | Oct 2007 | B2 |
7291142 | Eberl et al. | Nov 2007 | B2 |
7306561 | Sathyanarayana | Dec 2007 | B2 |
7335052 | D'Sa | Feb 2008 | B2 |
7347820 | Bonnefous | Mar 2008 | B2 |
7347821 | Dkyba et al. | Mar 2008 | B2 |
7347857 | Anderson et al. | Mar 2008 | B2 |
7361144 | Levrier et al. | Apr 2008 | B2 |
7422591 | Phan | Sep 2008 | B2 |
7438714 | Phan | Oct 2008 | B2 |
7455669 | Swanson | Nov 2008 | B2 |
7488289 | Suorsa et al. | Feb 2009 | B2 |
7507205 | Borovsky et al. | Mar 2009 | B2 |
7519410 | Taimisto et al. | Apr 2009 | B2 |
7529393 | Peszynski et al. | May 2009 | B2 |
7534207 | Shehada et al. | May 2009 | B2 |
7544164 | Knowles et al. | Jun 2009 | B2 |
7549988 | Eberl et al. | Jun 2009 | B2 |
7569052 | Phan et al. | Aug 2009 | B2 |
7578791 | Rafter | Aug 2009 | B2 |
7582083 | Swanson | Sep 2009 | B2 |
7585310 | Phan et al. | Sep 2009 | B2 |
7610073 | Fuimaono et al. | Oct 2009 | B2 |
7648462 | Jenkins et al. | Jan 2010 | B2 |
7697972 | Verard et al. | Apr 2010 | B2 |
7704208 | Thiele | Apr 2010 | B2 |
7720420 | Kajita | May 2010 | B2 |
7727231 | Swanson | Jun 2010 | B2 |
7736362 | Eberl et al. | Jun 2010 | B2 |
7740629 | Anderson et al. | Jun 2010 | B2 |
7758508 | Thiele et al. | Jul 2010 | B1 |
7766833 | Lee et al. | Aug 2010 | B2 |
7776033 | Swanson | Aug 2010 | B2 |
7785324 | Eberl | Aug 2010 | B2 |
7794398 | Salgo | Sep 2010 | B2 |
7796789 | Salgo et al. | Sep 2010 | B2 |
7799025 | Wellman | Sep 2010 | B2 |
7815572 | Loupas | Oct 2010 | B2 |
7819863 | Eggers et al. | Oct 2010 | B2 |
7837624 | Hossack et al. | Nov 2010 | B1 |
7859170 | Knowles et al. | Dec 2010 | B2 |
7862561 | Swanson et al. | Jan 2011 | B2 |
7862562 | Eberl | Jan 2011 | B2 |
7879029 | Jimenez | Feb 2011 | B2 |
7892228 | Landis et al. | Feb 2011 | B2 |
7894871 | Wittkampf et al. | Feb 2011 | B2 |
7918850 | Govari et al. | Apr 2011 | B2 |
7957817 | Gillespie et al. | Jun 2011 | B1 |
7996085 | Levin | Aug 2011 | B2 |
8016822 | Swanson | Sep 2011 | B2 |
8048028 | Horn et al. | Nov 2011 | B2 |
8103327 | Harlev et al. | Jan 2012 | B2 |
8128617 | Bencini et al. | Mar 2012 | B2 |
8160690 | Wilfley et al. | Apr 2012 | B2 |
8162935 | Paul et al. | Apr 2012 | B2 |
8265745 | Hauck et al. | Sep 2012 | B2 |
8267926 | Paul et al. | Sep 2012 | B2 |
8290578 | Schneider | Oct 2012 | B2 |
8317783 | Cao et al. | Nov 2012 | B2 |
8369922 | Paul et al. | Feb 2013 | B2 |
8400164 | Osadchy et al. | Mar 2013 | B2 |
8403925 | Miller et al. | Mar 2013 | B2 |
8406866 | Deno et al. | Mar 2013 | B2 |
8414579 | Kim et al. | Apr 2013 | B2 |
8449535 | Deno et al. | May 2013 | B2 |
8454538 | Wittkampf et al. | Jun 2013 | B2 |
8454589 | Deno et al. | Jun 2013 | B2 |
8489184 | Wilfley et al. | Jul 2013 | B2 |
8579889 | Bencini | Nov 2013 | B2 |
8583215 | Lichtenstein | Nov 2013 | B2 |
8603084 | Fish et al. | Dec 2013 | B2 |
8603085 | Jimenez | Dec 2013 | B2 |
8644950 | Hauck | Feb 2014 | B2 |
8657814 | Werneth et al. | Feb 2014 | B2 |
8672936 | Thao et al. | Mar 2014 | B2 |
8679109 | Paul et al. | Mar 2014 | B2 |
8728077 | Paul et al. | May 2014 | B2 |
8740900 | Kim et al. | Jun 2014 | B2 |
8755860 | Paul et al. | Jun 2014 | B2 |
8771343 | Weber et al. | Jul 2014 | B2 |
8876817 | Avitall et al. | Nov 2014 | B2 |
8894643 | Watson et al. | Nov 2014 | B2 |
8906011 | Gelbart et al. | Dec 2014 | B2 |
8945015 | Rankin et al. | Feb 2015 | B2 |
8998890 | Paul et al. | Apr 2015 | B2 |
9089340 | Hastings et al. | Jul 2015 | B2 |
9125565 | Hauck | Sep 2015 | B2 |
9125668 | Subramaniam et al. | Sep 2015 | B2 |
9168004 | Gliner et al. | Oct 2015 | B2 |
9173586 | Deno et al. | Nov 2015 | B2 |
9211156 | Kim et al. | Dec 2015 | B2 |
9241687 | McGee | Jan 2016 | B2 |
9241761 | Rankin et al. | Jan 2016 | B2 |
9254163 | Paul et al. | Feb 2016 | B2 |
9265434 | Merschon et al. | Feb 2016 | B2 |
9271782 | Paul et al. | Mar 2016 | B2 |
9283026 | Paul et al. | Mar 2016 | B2 |
9370329 | Tun et al. | Jun 2016 | B2 |
9393072 | Kim et al. | Jul 2016 | B2 |
9463064 | Subramaniam et al. | Oct 2016 | B2 |
20010029371 | Kordis | Oct 2001 | A1 |
20020087208 | Koblish et al. | Jul 2002 | A1 |
20020165448 | Ben-Haim et al. | Nov 2002 | A1 |
20020198521 | Maguire | Dec 2002 | A1 |
20030013958 | Govari et al. | Jan 2003 | A1 |
20030088240 | Saadat | May 2003 | A1 |
20030158548 | Phan et al. | Aug 2003 | A1 |
20030158549 | Swanson | Aug 2003 | A1 |
20030229286 | Lenker | Dec 2003 | A1 |
20040006268 | Gilboa et al. | Jan 2004 | A1 |
20040082860 | Haissaguerre | Apr 2004 | A1 |
20040092806 | Sagon et al. | May 2004 | A1 |
20040116793 | Taimisto et al. | Jun 2004 | A1 |
20040147920 | Keidar | Jul 2004 | A1 |
20040162556 | Swanson | Aug 2004 | A1 |
20040186467 | Swanson et al. | Sep 2004 | A1 |
20040210136 | Varghese et al. | Oct 2004 | A1 |
20040215177 | Swanson | Oct 2004 | A1 |
20040215186 | Cornelius et al. | Oct 2004 | A1 |
20050033331 | Burnett et al. | Feb 2005 | A1 |
20050059862 | Phan | Mar 2005 | A1 |
20050059962 | Phan et al. | Mar 2005 | A1 |
20050059963 | Phan et al. | Mar 2005 | A1 |
20050059965 | Eberl et al. | Mar 2005 | A1 |
20050065506 | Phan | Mar 2005 | A1 |
20050065508 | Johnson et al. | Mar 2005 | A1 |
20050070894 | McClurken | Mar 2005 | A1 |
20050090817 | Phan | Apr 2005 | A1 |
20050119545 | Swanson | Jun 2005 | A1 |
20050119648 | Swanson | Jun 2005 | A1 |
20050119649 | Swanson | Jun 2005 | A1 |
20050119653 | Swanson | Jun 2005 | A1 |
20050119654 | Swanson et al. | Jun 2005 | A1 |
20050124881 | Kanai et al. | Jun 2005 | A1 |
20050187544 | Swanson et al. | Aug 2005 | A1 |
20050203597 | Yamazaki et al. | Sep 2005 | A1 |
20050228286 | Messerly et al. | Oct 2005 | A1 |
20050228504 | Demarais | Oct 2005 | A1 |
20050273060 | Levy et al. | Dec 2005 | A1 |
20060030919 | Mrva et al. | Feb 2006 | A1 |
20060089634 | Anderson et al. | Apr 2006 | A1 |
20060100522 | Yuan et al. | May 2006 | A1 |
20060161146 | Cornelius et al. | Jul 2006 | A1 |
20060247607 | Cornelius et al. | Nov 2006 | A1 |
20060247683 | Danek et al. | Nov 2006 | A1 |
20060253028 | Lam et al. | Nov 2006 | A1 |
20060253116 | Avitall et al. | Nov 2006 | A1 |
20070003811 | Zerfass et al. | Jan 2007 | A1 |
20070016054 | Yuan et al. | Jan 2007 | A1 |
20070016059 | Morimoto et al. | Jan 2007 | A1 |
20070016228 | Salas | Jan 2007 | A1 |
20070021744 | Creighton | Jan 2007 | A1 |
20070049925 | Phan et al. | Mar 2007 | A1 |
20070055225 | Dodd, III et al. | Mar 2007 | A1 |
20070073135 | Lee et al. | Mar 2007 | A1 |
20070088345 | Larson et al. | Apr 2007 | A1 |
20070165916 | Cloutier et al. | Jul 2007 | A1 |
20070167813 | Lee et al. | Jul 2007 | A1 |
20070181139 | Hauck | Aug 2007 | A1 |
20070225610 | Mickley et al. | Sep 2007 | A1 |
20070238997 | Camus | Oct 2007 | A1 |
20070270794 | Anderson et al. | Nov 2007 | A1 |
20080009733 | Saksena | Jan 2008 | A1 |
20080015568 | Paul et al. | Jan 2008 | A1 |
20080025145 | Peszynski et al. | Jan 2008 | A1 |
20080051841 | Swerdlow et al. | Feb 2008 | A1 |
20080058836 | Moll et al. | Mar 2008 | A1 |
20080086073 | McDaniel | Apr 2008 | A1 |
20080091109 | Abraham | Apr 2008 | A1 |
20080140065 | Rioux et al. | Jun 2008 | A1 |
20080161705 | Podmore et al. | Jul 2008 | A1 |
20080161795 | Wang et al. | Jul 2008 | A1 |
20080161796 | Cao et al. | Jul 2008 | A1 |
20080195089 | Thiagalingam et al. | Aug 2008 | A1 |
20080228111 | Nita | Sep 2008 | A1 |
20080243214 | Koblish | Oct 2008 | A1 |
20080275428 | Tegg et al. | Nov 2008 | A1 |
20080281322 | Sherman et al. | Nov 2008 | A1 |
20080287803 | Li et al. | Nov 2008 | A1 |
20080300454 | Goto | Dec 2008 | A1 |
20080312521 | Solomon | Dec 2008 | A1 |
20080312713 | Wilfley et al. | Dec 2008 | A1 |
20090005771 | Lieber et al. | Jan 2009 | A1 |
20090030312 | Hadjicostis | Jan 2009 | A1 |
20090048591 | Ibrahim et al. | Feb 2009 | A1 |
20090056344 | Poch | Mar 2009 | A1 |
20090062790 | Malchano et al. | Mar 2009 | A1 |
20090062795 | Vakharia et al. | Mar 2009 | A1 |
20090076390 | Lee et al. | Mar 2009 | A1 |
20090093810 | Subramaniam et al. | Apr 2009 | A1 |
20090093811 | Koblish et al. | Apr 2009 | A1 |
20090099472 | Remmert et al. | Apr 2009 | A1 |
20090131932 | Vakharia et al. | May 2009 | A1 |
20090163904 | Miller et al. | Jun 2009 | A1 |
20090171341 | Pope et al. | Jul 2009 | A1 |
20090171345 | Miller et al. | Jul 2009 | A1 |
20090177069 | Razavi | Jul 2009 | A1 |
20090177111 | Miller et al. | Jul 2009 | A1 |
20090182316 | Bencini | Jul 2009 | A1 |
20090209950 | Starksen | Aug 2009 | A1 |
20090216125 | Lenker | Aug 2009 | A1 |
20090240247 | Rioux et al. | Sep 2009 | A1 |
20090259274 | Simon et al. | Oct 2009 | A1 |
20090275827 | Aiken et al. | Nov 2009 | A1 |
20090281541 | Ibrahim et al. | Nov 2009 | A1 |
20090287202 | Ingle et al. | Nov 2009 | A1 |
20090292209 | Hadjicostis | Nov 2009 | A1 |
20090299355 | Bencini et al. | Dec 2009 | A1 |
20090299360 | Ormsby | Dec 2009 | A1 |
20090306643 | Pappone et al. | Dec 2009 | A1 |
20100010487 | Phan et al. | Jan 2010 | A1 |
20100057072 | Roman et al. | Mar 2010 | A1 |
20100076402 | Mazzone et al. | Mar 2010 | A1 |
20100094274 | Narayan et al. | Apr 2010 | A1 |
20100106155 | Anderson et al. | Apr 2010 | A1 |
20100113938 | Park et al. | May 2010 | A1 |
20100145221 | Brunnett et al. | Jun 2010 | A1 |
20100152728 | Park et al. | Jun 2010 | A1 |
20100168557 | Deno et al. | Jul 2010 | A1 |
20100168568 | Sliwa | Jul 2010 | A1 |
20100168570 | Sliwa et al. | Jul 2010 | A1 |
20100168831 | Korivi et al. | Jul 2010 | A1 |
20100241117 | Paul et al. | Sep 2010 | A1 |
20100249599 | Hastings et al. | Sep 2010 | A1 |
20100249603 | Hastings et al. | Sep 2010 | A1 |
20100249604 | Hastings et al. | Sep 2010 | A1 |
20100298826 | Leo et al. | Nov 2010 | A1 |
20100331658 | Kim et al. | Dec 2010 | A1 |
20110028820 | Lau et al. | Feb 2011 | A1 |
20110034915 | Ibrahim et al. | Feb 2011 | A1 |
20110071400 | Hastings et al. | Mar 2011 | A1 |
20110071401 | Hastings et al. | Mar 2011 | A1 |
20110112569 | Friedman et al. | May 2011 | A1 |
20110125143 | Gross et al. | May 2011 | A1 |
20110130648 | Beeckler et al. | Jun 2011 | A1 |
20110137153 | Govari et al. | Jun 2011 | A1 |
20110144491 | Sliwa et al. | Jun 2011 | A1 |
20110144524 | Fish et al. | Jun 2011 | A1 |
20110160584 | Paul et al. | Jun 2011 | A1 |
20110237933 | Cohen | Sep 2011 | A1 |
20110282249 | Tsoref et al. | Nov 2011 | A1 |
20110319782 | Sweeney et al. | Dec 2011 | A1 |
20120004547 | Harks et al. | Jan 2012 | A1 |
20120095347 | Adam et al. | Apr 2012 | A1 |
20120101398 | Ramanathan et al. | Apr 2012 | A1 |
20120116537 | Liebetanz | May 2012 | A1 |
20120136346 | Condie et al. | May 2012 | A1 |
20120136348 | Condie et al. | May 2012 | A1 |
20120136351 | Weekamp et al. | May 2012 | A1 |
20120172698 | Hastings et al. | Jul 2012 | A1 |
20120172727 | Hastings et al. | Jul 2012 | A1 |
20120172871 | Hastings et al. | Jul 2012 | A1 |
20120238897 | Wilfley et al. | Sep 2012 | A1 |
20120310064 | McGee | Dec 2012 | A1 |
20120330304 | Vegesna et al. | Dec 2012 | A1 |
20130023784 | Schneider et al. | Jan 2013 | A1 |
20130023897 | Wallace | Jan 2013 | A1 |
20130060245 | Grunewald et al. | Mar 2013 | A1 |
20130066312 | Subramaniam et al. | Mar 2013 | A1 |
20130066315 | Subramaniam et al. | Mar 2013 | A1 |
20130079763 | Heckel et al. | Mar 2013 | A1 |
20130165926 | Mathur et al. | Jun 2013 | A1 |
20130172715 | Just et al. | Jul 2013 | A1 |
20130172742 | Rankin et al. | Jul 2013 | A1 |
20130172875 | Govari et al. | Jul 2013 | A1 |
20130184706 | Gelbart et al. | Jul 2013 | A1 |
20130190747 | Koblish et al. | Jul 2013 | A1 |
20130197363 | Rankin et al. | Aug 2013 | A1 |
20130226169 | Miller et al. | Aug 2013 | A1 |
20130274582 | Afonso et al. | Oct 2013 | A1 |
20130331739 | Gertner | Dec 2013 | A1 |
20130345537 | Thakur et al. | Dec 2013 | A1 |
20140012251 | Himmelstein et al. | Jan 2014 | A1 |
20140058375 | Koblish | Feb 2014 | A1 |
20140066764 | Subramaniam et al. | Mar 2014 | A1 |
20140073893 | Bencini | Mar 2014 | A1 |
20140075753 | Haarer et al. | Mar 2014 | A1 |
20140081111 | Tun et al. | Mar 2014 | A1 |
20140081112 | Kim et al. | Mar 2014 | A1 |
20140081113 | Cohen et al. | Mar 2014 | A1 |
20140081262 | Koblish et al. | Mar 2014 | A1 |
20140100563 | Govari et al. | Apr 2014 | A1 |
20140107453 | Maskara et al. | Apr 2014 | A1 |
20140107636 | Bencini | Apr 2014 | A1 |
20140128757 | Banet et al. | May 2014 | A1 |
20140194867 | Fish et al. | Jul 2014 | A1 |
20140200429 | Spector et al. | Jul 2014 | A1 |
20140200430 | Spector | Jul 2014 | A1 |
20140214028 | Gelbart et al. | Jul 2014 | A1 |
20140228713 | Thao et al. | Aug 2014 | A1 |
20140243917 | Morley et al. | Aug 2014 | A1 |
20140261985 | Selkee | Sep 2014 | A1 |
20140276052 | Rankin et al. | Sep 2014 | A1 |
20140276811 | Koblish et al. | Sep 2014 | A1 |
20140330150 | Thakur et al. | Nov 2014 | A1 |
20140336518 | Shuros et al. | Nov 2014 | A1 |
20140364715 | Hauck | Dec 2014 | A1 |
20140364843 | Paul et al. | Dec 2014 | A1 |
20140364848 | Heimbecher et al. | Dec 2014 | A1 |
20150005624 | Hauck et al. | Jan 2015 | A1 |
20150011995 | Avitall et al. | Jan 2015 | A1 |
20150018813 | Gliner | Jan 2015 | A1 |
20150133914 | Koblish | May 2015 | A1 |
20150133920 | Rankin et al. | May 2015 | A1 |
20150265341 | Koblish | Sep 2015 | A1 |
20150265348 | Avitall et al. | Sep 2015 | A1 |
20150342672 | Bencini et al. | Dec 2015 | A1 |
20150374436 | Subramaniam et al. | Dec 2015 | A1 |
20160008065 | Gliner et al. | Jan 2016 | A1 |
20160100884 | Fay et al. | Apr 2016 | A1 |
20160113712 | Cheung et al. | Apr 2016 | A1 |
Number | Date | Country |
---|---|---|
2682055 | Oct 2008 | CA |
2847846 | Mar 2013 | CA |
2848053 | Mar 2013 | CA |
1269708 | Oct 2000 | CN |
1455655 | Nov 2003 | CN |
1942145 | Apr 2007 | CN |
102271607 | Dec 2011 | CN |
102573986 | Jul 2012 | CN |
103917185 | Jul 2014 | CN |
103987336 | Aug 2014 | CN |
104619259 | May 2015 | CN |
104640513 | May 2015 | CN |
104661609 | May 2015 | CN |
1343426 | Sep 2003 | EP |
1343427 | Sep 2003 | EP |
1502542 | Feb 2005 | EP |
1547537 | Jun 2005 | EP |
0985423 | Apr 2006 | EP |
1717601 | Nov 2006 | EP |
1935332 | Jun 2008 | EP |
2755587 | Jul 2014 | EP |
2755588 | Jul 2014 | EP |
2136702 | Jul 2015 | EP |
2897545 | Jul 2015 | EP |
2000000242 | Jan 2000 | JP |
200083918 | Mar 2000 | JP |
2000504242 | Apr 2000 | JP |
2002528039 | Aug 2002 | JP |
2003504090 | Feb 2003 | JP |
2004503335 | Feb 2004 | JP |
2006239414 | Sep 2006 | JP |
2007163559 | Jun 2007 | JP |
2007244857 | Sep 2007 | JP |
2009142653 | Dec 2008 | JP |
2009518150 | May 2009 | JP |
2010522623 | Jul 2010 | JP |
2011142995 | Jul 2011 | JP |
2011525842 | Sep 2011 | JP |
2012531967 | Dec 2012 | JP |
5336465 | Nov 2013 | JP |
2014012174 | Jan 2014 | JP |
2014531244 | Nov 2014 | JP |
2015501162 | Jan 2015 | JP |
2015509027 | Mar 2015 | JP |
20100021401 | Feb 2010 | KR |
101490374 | Feb 2015 | KR |
WO9221278 | Dec 1992 | WO |
WO9413358 | Jun 1994 | WO |
WO9725916 | Jul 1997 | WO |
WO9725917 | Jul 1997 | WO |
WO9736541 | Oct 1997 | WO |
9745156 | Dec 1997 | WO |
WO9858681 | Dec 1998 | WO |
9909879 | Mar 1999 | WO |
WO9927862 | Jun 1999 | WO |
WO0029062 | May 2000 | WO |
WO0158372 | Aug 2001 | WO |
WO0164145 | Sep 2001 | WO |
WO0168173 | Sep 2001 | WO |
WO0205868 | Jan 2002 | WO |
WO0209599 | Feb 2002 | WO |
WO0219934 | Mar 2002 | WO |
WO0247569 | Jun 2002 | WO |
WO02102234 | Dec 2002 | WO |
WO03039338 | May 2003 | WO |
WO2007079278 | Jul 2007 | WO |
WO2008046031 | Apr 2008 | WO |
WO2008118992 | Oct 2008 | WO |
WO2009032421 | Mar 2009 | WO |
2009043824 | Apr 2009 | WO |
2009048943 | Apr 2009 | WO |
2010054409 | May 2010 | WO |
WO2010056771 | May 2010 | WO |
2010082146 | Jul 2010 | WO |
2011008444 | Jan 2011 | WO |
2011033421 | Mar 2011 | WO |
WO2011024133 | Mar 2011 | WO |
WO2011089537 | Jul 2011 | WO |
2011101778 | Aug 2011 | WO |
WO2011095937 | Aug 2011 | WO |
2012001595 | Jan 2012 | WO |
WO2012001595 | Jan 2012 | WO |
WO2012049621 | Apr 2012 | WO |
WO2012066430 | May 2012 | WO |
2012161880 | Nov 2012 | WO |
WO2012151301 | Nov 2012 | WO |
2012166239 | Dec 2012 | WO |
2013040201 | Mar 2013 | WO |
2013040297 | Mar 2013 | WO |
2014036439 | Mar 2014 | WO |
2014058375 | Apr 2014 | WO |
2014072879 | May 2014 | WO |
2014152575 | Sep 2014 | WO |
2015143061 | Sep 2015 | WO |
2015183635 | Dec 2015 | WO |
Entry |
---|
International Preliminary Report on Patentability issued in PCT/US2015/021300 mailed Sep. 29, 2016, 7 pages. |
International Search Report and Written Opinion issued in PCT/US2015/066874, mailed Apr. 1, 2016, 11 pages. |
Extended European Search Report issued in EP Application No. 15174537.9, issued Mar. 2, 2016, 7 pages. |
Goldberg, S. Nahum et al., “Variables Affecting Proper System Grounding for Radiofrequency Ablation in an Animal Model”, JVIR, vol. 11, No. 8, Sep. 2000, pp. 1069-1075. |
Haverkamp, W., et. al. Coagulation of Ventricular Myocardium Using Radiofrequency Alternating Current: Bio-Physical Aspects and Experimental Findings, PACE, 12:187-195, Jan. 1989, Part II. |
International Preliminary Examination Report issued in PCT/US2013/060612, completed Mar. 24, 2015, 10 pages. |
International Preliminary Report on Patentability issued in PCT/US2008/058324, mailed Sep. 29, 2009, 9 pages. |
International Preliminary Report on Patentability issued in PCT/US2012/055155, issued Mar. 18, 2014, 11 pages. |
International Preliminary Report on Patentability issued in PCT/US2012/055309, issued on Mar. 18, 2014, 8 pages. |
International Preliminary Report on Patentability issued in PCT/US2013/056211, completed Feb. 24, 2015, 5 pages. |
International Preliminary Report on Patentability issued in PCT/US2013/058105, completed Mar. 10, 2015. |
International Preliminary Report on Patentability issued in PCT/US2013/060194, mailed Mar. 24, 2015, 6 pages. |
International Preliminary Report on Patentability issued in PCT/US2014/027491, mailed Sep. 24, 2015, 12 pages. |
International Preliminary Report on Patentablity issued in PCT/US2013/060183, mailed Mar. 24, 2015, 6 pages. |
International Search Report and Written Opinion issued in PCT/US2008/058324, dated Aug. 18, 2008, 11 pages. |
International Search Report and Written Opinion issued in PCT/US2012/031819, mailed Sep. 27, 2012, 16 pages. |
International Search Report and Written Opinion issued in PCT/US2012/055155, mailed Mar. 11, 2013, 19 pages. |
International Search Report and Written Opinion issued in PCT/US2012/055309, mailed Nov. 19, 2012, 13 pages. |
International Search Report and Written Opinion issued in PCT/US2012/072061, mailed Mar. 21, 2013, 9 pages. |
International Search Report and Written Opinion issued in PCT/US2013/020503, mailed Mar. 20, 2013, 10 pages. |
International Search Report and Written Opinion issued in PCT/US2013/021013, mailed Apr. 5, 2013, 14 pages. |
International Search Report and Written Opinion issued in PCT/US2013/056211, mailed Jan. 20, 2014. |
International Search Report and Written Opinion issued in PCT/US2013/058105, mailed Nov. 22, 2013, 16 pages. |
International Search Report and Written Opinion issued in PCT/US2013/060183, mailed Jan. 27, 2014, 10 pages. |
International Search Report and Written Opinion issued in PCT/US2013/060194, mailed Jan. 29, 2014. |
International Search Report and Written Opinion issued in PCT/US2013/060194, mailed Jan. 29, 2014, 10 pages. |
International Search Report and Written Opinion issued in PCT/US2013/060612, mailed Feb. 28, 2014, 16 pages. |
International Search Report and Written Opinion issued in PCT/US2014/027491, mailed Sep. 23, 2014, 17 pages. |
International Search Report and Written Opinion issued in PCT/US2015/021300, mailed Jun. 9, 2015, 11 pages. |
International Search Report and Written Opinion issued in PCT/US2015/055173, mailed Jan. 18, 2016, 11 pages. |
International Search Report and Written Opinion issued in PCT/US2015/057242, mailed Jan. 15, 2016, 11 pages. |
International Search Report and Written Opinion issued in PCT/US2016/028006 mailed Jul. 12, 2016, 12 pages. |
International Search Report and Written Opinion issued in PCTUS2015/031591, mailed Aug. 17, 2015, 11 pages. |
Invitation to Pay Additional Fees and Partial International Search Report issued in PCT/US2014/027491, mailed Jul. 28, 2014, 5 pages. |
Machi MD, Junji, “Prevention of Dispersive Pad Skin Burns During RFA by a Simple Method”, Editorial Comment, Surg Laparosc Endosc Percutan Tech, vol. 13, No. 6, Dec. 2003, pp. 372-373. |
Neufeld, Gordon R. et al., “Electrical Impedance Properties of the Body and the Problem of Alternate-site Burns During Electrosurgery”, Medical Instrumentation, vol. 19, No. 2, Mar.-Apr. 1985, pp. 83-87. |
Partial International Search Report issued in PCT/US2012/055155, mailed Dec. 20, 2012, 7 pages. |
Patriciu, A. et al., “Detecting Skin Burns induced by Surface Electrodes”, published in Engineering in Medicine and Biology Society, 2001. Proceedings of the 23rd Annual International Conference of the IEEE, vol. 3, pp. 3129-3131. |
Piorkolwski, Christopher et al., “First in Human Validation of Impedance-Based Catheter Tip-to-Tissue Contact Assessment in the Left Atrium”, Journal of Cardiovascular Electrophysiology, vol. 20, No. 12, Dec. 1, 2009, pp. 1366-1373. |
Pires, L. A., et. al. Temperature-guided Radiofrequency Catheter Ablation of Closed-Chest Ventricular Myocardium with a Novel Thermistor-Tipped Catheter. American Heart Journal, 127(6):1614-1618, Jun. 1994. |
Price, Adam et al., “Novel Ablation Catheter Technology that Improves Mapping Resolution and Monitoring of Lesion Maturation”, The Journal of Innovations in Cardiac Rhythm Management, vol. 3, 2002, pp. 599-609. |
Price, Adam et al., “PO3-39 Pin Electrodes Improve Resolution: Enhanced Monitoring of Radiofrequency Lesions in the Voltage and Frequency Domains”, Heart Rhythm 2010, 31st Annual Scientific Sessions, May 12-15 in Denver Colorado. |
Ring, E. R., et. al. Catheter Ablation of the Ventricular Septum with Radiofrequency Energy. American Heart Journal, 117(6)1233-1240, Jun. 1989. |
Steinke, Karin et al., “Dispersive Pad Site burns Wth Modern Radiofrequency Ablation Equipment”, Surg Laparosc Endosc Percutan Tech, vol. 13, No. 6, Dec. 2003, pp. 366-371. |
Zachary, J.M. et al., “PO4-86 Pin Electrodes Provide Enhanced Resolution Enabling Titration of Radiofrequency Duration to Lesion Maturation”, Heart Rhythm 2011, 32 Annual Scientific Sessions, May 4-7, San Francisco, CA. |
Extended European Search Report issued in EP Application 16182627.6, mailed Nov. 8, 2016, 5 pages. |
International Preliminary Report on Patentability issued in PCT/US2015/031591, mailed Dec. 6, 2016, 7 pages. |
Number | Date | Country | |
---|---|---|---|
20160174865 A1 | Jun 2016 | US |
Number | Date | Country | |
---|---|---|---|
62093771 | Dec 2014 | US |